Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022451 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib in Treating Young Patients With Refractory Leukemia
A Phase 1 study of Leukemia, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Study locations
NCT00022451 is a Phase 1 study of Leukemia that has completed, run by National Institutes of Health Clinical Center (CC). The trial reports 20 study locations across 11 states.
The verdict
NCT00022451, a Phase 1 study of Leukemia, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of tipifarnib in treating young patients who have refractory leukemia.
Conditions Studied
Interventions
- DRUG tipifarnib
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Children's Hospital Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Comprehensive Cancer Center - San Francisco
- Stanford Cancer Center at Stanford University Medical Center - Stanford
Georgia
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus - Atlanta
- MBCCOP-Medical College of Georgia Cancer Center - Augusta
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Massachusetts
- Floating Hospital for Children - Boston
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Shands Cancer Center at the University of Florida Health Science Center - Gainesville
Illinois
- Children's Memorial Hospital - Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022451
The ClinicalTrials.gov registry entry for NCT00022451 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which tipifarnib is the first listed.
NCT00022451 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Georgia, Maryland.
Frequently Asked Questions
What is clinical trial NCT00022451 about?
NCT00022451 is a clinical study titled "Tipifarnib in Treating Young Patients With Refractory Leukemia". RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of tipifarnib in treating young patients who have refractory leukemia.
What is the current status of trial NCT00022451?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-06. Estimated completion is 2005-03.
What conditions does trial NCT00022451 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00022451?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00022451?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022451 being conducted?
This trial has 20 study locations across Arkansas, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.